News
CRMD
4.660
-3.72%
-0.180
Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11
Benzinga · 9h ago
Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals
NASDAQ · 11h ago
CorMedix Price Target Cut to $13.00/Share From $15.00 by Oppenheimer
Dow Jones · 11h ago
Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
Benzinga · 12h ago
CorMedix Price Target Cut to $14.00/Share From $15.00 by RBC Capital
Dow Jones · 12h ago
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 12h ago
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14
Benzinga · 12h ago
CorMedix price target lowered to $13 from $15 at Oppenheimer
TipRanks · 13h ago
CorMedix Price Target Cut to $12.00/Share From $14.00 by Needham
Dow Jones · 16h ago
CorMedix Is Maintained at Buy by Needham
Dow Jones · 16h ago
Heron’s 18.3% Stake in Cormedix Raises Governance Risks and Potential Valuation Overhang
TipRanks · 21h ago
Cormedix Q3 2026 Earnings Call Transcript
Benzinga · 1d ago
CorMedix reports Q3 EPS (19c) vs. $1.26 last year
TipRanks · 1d ago
*CorMedix Suspends 2027 DefenCath Revenue Guidance Due to Recently Announced Changes to CMS Reimbursement Framework >CRMD
Dow Jones · 1d ago
*CorMedix Backs 2026 View of Rev $325M-$345M >CRMD
Dow Jones · 1d ago
*CorMedix Narrows 2026 Adjusted Ebitda View to $130M-$140M >CRMD
Dow Jones · 1d ago
Press Release: Cormedix Therapeutics Reports -3-
Dow Jones · 1d ago
CorMedix: Q3 Earnings Snapshot
Barchart · 1d ago
Here are the major earnings before the open Thursday
Seeking Alpha · 2d ago
CorMedix Announces Agreement to Acquire Heron’s Commercial Assets
TipRanks · 3d ago
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.